{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:14:12Z","timestamp":1789172052860,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.7759\/cureus.98350","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:47:31Z","timestamp":1764748051000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Changes in Optical Coherence Tomography (OCT) Biomarkers After Oral Eplerenone Therapy in Chronic Central Serous Chorioretinopathy and Their Correlation to Functional Visual Outcome"],"prefix":"10.7759","author":[{"given":"Priyadarshini","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruttendu","family":"Moharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmugasundaram","family":"Palanisamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagabat","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijnya B","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip K","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sucheta","family":"Parija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311096","article-title":"Spironolactone versus observation in the treatment of acute central serous chorioretinopathy","volume":"102","author":"Sun X","year":"2018","unstructured":"Sun X, Shuai Y, Fang W, Li J, Ge W, Yuan S, Liu Q. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol. 2018, 102:1060-5. 10.1136\/bjophthalmol-2017-311096","journal-title":"Br J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71938-3","article-title":"Central serous chorioretinopathy and heart rate variability analysis with a smartphone application","volume":"10","author":"Takeshima K","year":"2020","unstructured":"Takeshima K, Tanaka K, Mori R, et al.. Central serous chorioretinopathy and heart rate variability analysis with a smartphone application. Sci Rep. 2020, 10:14949. 10.1038\/s41598-020-71938-3","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.09.034","article-title":"Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving central serous chorioretinopathy","volume":"198","author":"Bousquet E","year":"2019","unstructured":"Bousquet E, Dhundass M, Lejoyeux R, et al.. Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving central serous chorioretinopathy. Am J Ophthalmol. 2019, 198:80-7. 10.1016\/j.ajo.2018.09.034","journal-title":"Am J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.104","article-title":"Therapeutic benefit of melatonin in refractory central serous chorioretinopathy","volume":"29","author":"Gramajo AL","year":"2015","unstructured":"Gramajo AL, Marquez GE, Torres VE, Ju\u00e1rez CP, Rosenstein RE, Luna JD. Therapeutic benefit of melatonin in refractory central serous chorioretinopathy. Eye (Lond). 2015, 29:1036-45. 10.1038\/eye.2015.104","journal-title":"Eye (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2013.015","article-title":"Treatment of central serous chorioretinopathy with beta-blocker metipranolol","volume":"159","author":"Chrapek O","year":"2015","unstructured":"Chrapek O, Jirkova B, Kandrnal V, Rehak J, Sin M. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159:120-3. 10.5507\/bp.2013.015","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study","volume":"35","author":"Bousquet E","year":"2015","unstructured":"Bousquet E, Beydoun T, Rothschild PR, et al.. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015, 35:2505-15. 10.1097\/IAE.0000000000000614","journal-title":"Retina"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001303","article-title":"Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes","volume":"37","author":"Gergely R","year":"2017","unstructured":"Gergely R, Kov\u00e1cs I, Schneider M, et al.. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina. 2017, 37:1084-91. 10.1097\/IAE.0000000000001303","journal-title":"Retina"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120952648","article-title":"Eplerenone for treatment of chronic central serous chorioretinopathy","volume":"31","author":"Fraenkel D","year":"2021","unstructured":"Fraenkel D, Suffo S, Langenbucher A, Seitz B, Abdin AD. Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2021, 31:1885-91. 10.1177\/1120672120952648","journal-title":"Eur J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-016-0377-2","article-title":"Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy","volume":"37","author":"Pichi F","year":"2017","unstructured":"Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. 2017, 37:1115-25. 10.1007\/s10792-016-0377-2","journal-title":"Int Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich A","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, et al.. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015, 48:82-118. 10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00385-1","article-title":"Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses","volume":"8","author":"Felipe CQ","year":"2022","unstructured":"Felipe CQ, Biancardi AL, Civile VT, Carvas Junior N, Serracarbassa PD, Koike MK. Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses. Int J Retina Vitreous. 2022, 8:34. 10.1186\/s40942-022-00385-1","journal-title":"Int J Retina Vitreous"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13491","article-title":"Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study","volume":"95","author":"Schwartz R","year":"2017","unstructured":"Schwartz R, Habot-Wilner Z, Martinez MR, et al.. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017, 95:e610-8. 10.1111\/aos.13491","journal-title":"Acta Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial","volume":"395","author":"Lotery A","year":"2020","unstructured":"Lotery A, Sivaprasad S, O'Connell A, et al.. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020, 395:294-303. 10.1016\/S0140-6736(19)32981-2","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00500-w","article-title":"Real-world practice patterns of eplerenone use for central serous chorioretinopathy","volume":"9","author":"Venkatesh R","year":"2023","unstructured":"Venkatesh R, Prabhu V, Joshi A, et al.. Real-world practice patterns of eplerenone use for central serous chorioretinopathy. Int J Retina Vitreous. 2023, 9:61. 10.1186\/s40942-023-00500-w","journal-title":"Int J Retina Vitreous"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48825-7","article-title":"Association between visual function and the integrity of residual ellipsoid zone in resolved central serous chorioretinopathy","volume":"9","author":"Fujita A","year":"2019","unstructured":"Fujita A, Aoyama Y, Tsuneyoshi S, et al.. Association between visual function and the integrity of residual ellipsoid zone in resolved central serous chorioretinopathy. Sci Rep. 2019, 9:12433. 10.1038\/s41598-019-48825-7","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/414480-evaluation-of-changes-in-optical-coherence-tomography-oct-biomarkers-after-oral-eplerenone-therapy-in-chronic-central-serous-chorioretinopathy-and-their-correlation-to-functional-visual-outcome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:47:31Z","timestamp":1764748051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/414480-evaluation-of-changes-in-optical-coherence-tomography-oct-biomarkers-after-oral-eplerenone-therapy-in-chronic-central-serous-chorioretinopathy-and-their-correlation-to-functional-visual-outcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.98350","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}